Atara Biotherapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
ATRA$8.10-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Income (Loss)
(In thousands, except per share amounts)
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Commercialization revenue | $120,772 | $128,940 |
| Total revenue | 120,772 | 128,940 |
| Costs and operating expenses: | ||
| Cost of commercialization revenue | 21,212 | 21,009 |
| Research and development expenses | 37,445 | 151,483 |
| General and administrative expenses | 26,253 | 39,886 |
| Total costs and operating expenses | 84,910 | 212,378 |
| Income (loss) from operations | 35,862 | (83,438) |
| Other income (expense), net: | ||
| Interest income | 683 | 2,110 |
| Interest expense | (3,792) | (4,615) |
| Other income (expense), net: | (34) | 528 |
| Total other income (expense), net | (3,143) | (1,977) |
| Income (loss) before provision for (benefit from) income taxes | 32,719 | (85,415) |
| Provision for (benefit from) income taxes | 31 | (12) |
| Net income (loss) | $32,688 | $(85,403) |
| Other comprehensive gain (loss): | ||
| Unrealized gain (loss) on available-for-sale securities | (7) | 212 |
| Comprehensive income (loss) | $32,681 | $(85,191) |
| Basis earnings (loss) per common share | $2.61 | $(11.41) |
| Diluted earnings (loss) per common share | $2.57 | $(11.41) |
| Basic weighted-average shares outstanding | 12,544 | 7,488 |
| Diluted weighted-average shares outstanding | 12,718 | 7,488 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.